Navicixizumab (Anti-DLL4)

製品コード：A2519        

印刷

Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.

製品説明

CAS No. 1638338-43-8
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype Human IgG2SA
Source CHO
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping Shipped under low temperature conditions

人間や獣医の診断であるか治療的な使用のためにでない。